1,207 results on '"Wen, Patrick Y"'
Search Results
2. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas
3. Clinical trial links oncolytic immunoactivation to survival in glioblastoma
4. Liquid biopsy epigenomic profiling for cancer subtyping
5. Molecular Profiling and Targeted Therapies in Gliomas
6. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
7. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling
8. Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping
9. Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival
10. Cavitation monitoring, treatment strategy, and acoustic simulations of focused ultrasound blood-brain barrier disruption in patients with glioblastoma
11. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
12. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
13. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
14. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
15. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
16. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
17. Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
18. Novel trial designs in neuro-oncology
19. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine
20. Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
21. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
22. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
23. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference
24. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
25. The design and evaluation of hybrid controlled trials that leverage external data and randomization
26. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma
27. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients
28. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis
29. Incidence and Predictors of Neurologic Death in Patients with Brain Metastases
30. Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities
31. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
32. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
33. Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.
34. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.
35. Leveraging external data in the design and analysis of clinical trials in neuro-oncology
36. IDH-mutant gliomas with additional class-defining molecular events
37. Therapeutic Advances in Neuro-Oncology
38. Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma
39. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide
40. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
41. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
42. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
43. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
44. Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.
45. Systematic characterization of antibody–drug conjugate targets in central nervous system tumors.
46. Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
47. Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET
48. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
49. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report
50. Medical and Neurological Management of Brain Tumor Complications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.